Breaking Down Kunshan Kersen Science & Technology Co.,Ltd. Financial Health: Key Insights for Investors

Kunshan Kersen Science & Technology Co., Ltd. (603626.SS) sits at a crossroads for investors: trailing twelve‑month revenue of CNY 3.21 billion (down 2.81% YoY) after a 2024 revenue peak of CNY 3.38 billion (up 30.26% from 2023), a market capitalization near CNY 6.66 billion and a P/S of 2.07 that contrasts with a troubling net loss of CNY 476.83 million in 2024 (losses up 69.4% YoY), EPS of -CNY 0.65, gross margin just 4.48% and an operating margin of -13.92%; balance sheet figures show total debt of CNY 1.71 billion against cash around CNY 372.7 million, debt/equity of 0.72, total assets CNY 5.12 billion and book value per share CNY 3.918 while liquidity metrics (current ratio 0.85, quick ratio 0.62) and a levered free cash flow of -CNY 20.04 million raise short‑term concerns even as operating cash flow is CNY 123.37 million-valuation and momentum data include a P/B of 3.52, enterprise value CNY 8.02 billion, a 25% one‑year share price rise and beta 0.45; growth levers cited are a planned Southeast Asia entry (targeting a $3 billion potential), a 2023 acquisition projected to boost market share ~15%, analyst‑projected revenue CAGR of 12% over five years, R&D spend ~10% of revenue and proprietary tech claiming 25% production efficiency gains-read on to examine how these figures translate into risk, runway and potential upside for investors

Kunshan Kersen Science & Technology Co.,Ltd. (603626.SS) - Revenue Analysis

• TTM revenue (ending Sep 30, 2025): CNY 3.21 billion (-2.81% YoY)
• Full-year 2024 revenue: CNY 3.38 billion (+30.26% vs. 2023)
• Q3 2025 revenue: CNY 870.73 million (-1.14% vs. Q3 2024)
• Revenue per employee: CNY 652,560 (4,924 employees)
• Price-to-Sales (P/S) ratio: 2.07
• Market capitalization: ~CNY 6.66 billion

• Momentum shift after 2024's double-digit growth - monitoring subsequent quarterly trends for stabilization or further decline.
• Revenue density vs. headcount: CNY 652,560 per employee suggests operational scale - compare to peers for productivity assessment.
• Valuation context: P/S 2.07 and market cap ~CNY 6.66 billion indicate the market prices modest premium relative to top-line generation.

Kunshan Kersen Science & Technology Co.,Ltd. (603626.SS) Profitability Metrics

Kunshan Kersen reported significant deterioration in profitability through 2024, driven by widening operational losses and narrow gross margins. Key headline figures for the trailing twelve months and 2024 results are summarized below.

• Net loss (2024): CNY 476.83 million (loss increased 69.4% vs. 2023)
• EPS (TTM): -CNY 0.65
• Operating margin (TTM): -13.92%
• Gross margin (TTM): 4.48%
• EBITDA margin (TTM): -3.48%
• Return on Equity (ROE): -17.87%

Implications for investors include severely constrained profit generation, margin compression at the gross level, and elevated operating losses that translate into negative EPS and ROE. For context on corporate direction and strategic priorities that may influence future profitability, see: Mission Statement, Vision, & Core Values (2026) of Kunshan Kersen Science & Technology Co.,Ltd.

Kunshan Kersen Science & Technology Co.,Ltd. (603626.SS) Debt vs. Equity Structure

• Leverage profile: Total debt of CNY 1.71 billion with a debt-to-equity of 0.72 signals moderate leverage-debt is material but not excessive versus equity.
• Liquidity constraints: Current ratio 0.85 and quick ratio 0.62 indicate the company may struggle to cover near-term obligations without converting inventory or raising cash.
• Cash coverage: Cash reserves (CNY 372.7m) cover only ~21.8% of total debt, implying limited buffer for debt servicing or unexpected cash needs.
• Balance sheet composition: Total assets of CNY 5.12 billion against liabilities of CNY 2.99 billion produce tangible equity supporting the book value per share of CNY 3.918.

Kunshan Kersen Science & Technology Co.,Ltd. (603626.SS) Liquidity and Solvency

• Operating cash flow (TTM): CNY 123.37 million - positive operational cash generation.
• Levered free cash flow (TTM): -CNY 20.04 million - negative free cash flow after debt-related cash flows.
• Interest coverage ratio: Not available - inability to directly assess coverage of interest expense from operating profits.
• Cash on hand: CNY 345.99 million - immediate liquidity buffer for near-term needs.
• Total liabilities: CNY 2.99 billion; Total assets: CNY 5.12 billion - debt-to-assets ≈ 58.5%.
• Total equity: CNY 2.13 billion - equity base supporting solvency.

Kunshan Kersen Science & Technology Co.,Ltd. (603626.SS) - Valuation Analysis

Key market and valuation metrics for Kunshan Kersen Science & Technology Co.,Ltd. provide a snapshot of how the market currently prices its revenue, assets and risk profile. Relevant context and investor-focused implications are summarized below.

• Market capitalization: CNY 6.66 billion
• Enterprise value (EV): CNY 8.02 billion (equity + net debt)
• Price-to-Sales (P/S): 2.07
• Price-to-Book (P/B): 3.52
• 12-month stock performance: +25%
• Beta: 0.45 (lower volatility vs. broader market)

Investor considerations:

• Relative valuation: P/S of 2.07 suggests moderate revenue multiple-compare with industry peers for context.
• Balance-sheet premium: P/B of 3.52 indicates investors expect above-book returns or intangible asset value.
• Takeover/transaction view: EV of CNY 8.02 billion frames any M&A premium versus current market cap.
• Risk-adjusted return: Beta 0.45 implies defensive characteristics; price appreciation of 25% indicates recent positive catalysts.

For historical context, ownership and how the company operates, see: Kunshan Kersen Science & Technology Co.,Ltd.: History, Ownership, Mission, How It Works & Makes Money

Kunshan Kersen Science & Technology Co.,Ltd. (603626.SS) - Risk Factors

Kunshan Kersen Science & Technology Co.,Ltd. (603626.SS) presents a mixed risk profile for investors driven by substantial recent losses, operational weakness, leverage and liquidity constraints, even as market sentiment has shown signs of improvement.

• Net loss: CNY 476.83 million in 2024, a 69.4% increase in losses versus 2023.
• Operating performance: Trailing twelve months operating margin of -13.92%, indicating operating inefficiency and margin pressure.
• Leverage: Debt-to-equity ratio of 0.72, reflecting a moderate reliance on debt financing relative to equity.
• Liquidity: Current ratio of 0.85, below 1.0, suggesting potential short-term liquidity stress in meeting obligations as they come due.
• Balance-sheet risk: Total liabilities of CNY 2.99 billion against total assets of CNY 5.12 billion, yielding a debt-to-assets ratio of ~58.5%.
• Market signal: Share price up ~25% over the past year, which may reflect investor optimism that could be sensitive to operational or macro developments.

Key scenarios investors should monitor:

• Operational turnaround: Improvement in operating margin from -13.92% to positive territory is critical to achieve sustainable profitability.
• Liquidity management: With a current ratio of 0.85, near-term cash flow and working capital solutions (e.g., receivables, inventory, short-term financing) are essential.
• Debt servicing and refinancing risk: Given total liabilities of CNY 2.99 billion and debt-to-assets ~58.5%, refinancing conditions and interest-rate exposure could materially affect financial stability.
• Market valuation sensitivity: The ~25% stock price rally may reverse quickly if operational metrics or earnings guidance disappoint.

For context on corporate direction and long-term priorities that could affect these risks, see: Mission Statement, Vision, & Core Values (2026) of Kunshan Kersen Science & Technology Co.,Ltd.

Kunshan Kersen Science & Technology Co.,Ltd. (603626.SS) - Growth Opportunities

Kunshan Kersen Science & Technology Co.,Ltd. (603626.SS) is positioning for accelerated expansion through geographic entry, M&A, R&D intensity, and strategic partnerships. Key quantified opportunities and implications for investor returns are summarized below.

• Planned Southeast Asia entry by Q3 2024 targeting an estimated addressable market of $3.0 billion over the next five years.
• Acquisition completed in 2023 expected to raise the company's market share by ~15% within two years, accelerating top-line scale.
• Analyst consensus projects revenue CAGR of 12% over the next five years (FY2024-FY2028).
• Ongoing R&D commitment of ~10% of annual revenue to new technology and product enhancements, supporting long-term margin expansion and product differentiation.
• Proprietary technology improvements are estimated to enhance production efficiency by ~25%, driving unit-cost advantages.
• Active pursuit of partnerships and joint ventures (local tech firms and European partners) to broaden channels and supply-chain resilience.

Projected revenue path (illustrative using FY2023 revenue baseline of CNY 1,200M):

• R&D dollar commitment (example): at CNY 1,200M baseline, ~CNY 120M/year allocated to R&D, rising in line with revenue growth (projected ~CNY 212M by FY2028).
• Efficiency upside: a 25% production efficiency gain can translate into meaningful gross margin improvement; e.g., a 5-8 percentage-point gross margin lift depending on cost structure and scale.
• Acquisition and regional expansion synergy: combined effects expected to compound the 12% CAGR target and improve unit economics through higher utilization and distribution leverage.

For company background and corporate context, see: Kunshan Kersen Science & Technology Co.,Ltd.: History, Ownership, Mission, How It Works & Makes Money